In addition to receiving an initial upfront payment of $120 million, UCB will also receive, after positive completion of a proof-of-concept study in Alzheimer's disease, further payments with a total potential consideration approaching $2 billion upon receipt of certain regulatory approvals and satisfying certain milestones, according to the vendor.

UCB noted that it will fund and perform the initial proof-of-concept study for the investigational monoclonal antibody drug in Alzheimer's disease. Once the study has been completed and results are available, Genentech will then have the right to proceed with clinical development or return full rights back to UCB, the company said.

Animal study turns in positive results for Moderna-NIH COVID-19 vaccine
Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, has been shown to induce immune responses and control upper and lower respiratory tract...

Extracellular RNA identifies new Alzheimer's biomarker
The association of extracellular RNA with upregulation of the phosphoglycerate dehydrogenase gene may be a useful presymptomatic biomarker for Alzheimer's...